Search Results - "Thall, P."

Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials by Thall, P., Fox, P., Wathen, J.

“…In recent years, various outcome adaptive randomization (AR) methods have been used to conduct comparative clinical trials. Rather than randomizing patients…”
Get full text

Phase I–II clinical trial design: a state-of-the-art paradigm for dose finding by Yan, F., Thall, P.F., Lu, K.H., Gilbert, M.R., Yuan, Y.

“…Conventional phase I algorithms for finding a phase-2 recommended dose (P2RD) based on toxicity alone is problematic because the maximum tolerated dose (MTD)…”
Get full text

A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer by Ajani, J.A., Xiao, L., Roth, J.A., Hofstetter, W.L., Walsh, G., Komaki, R., Liao, Z., Rice, D.C., Vaporciyan, A.A., Maru, D.M., Lee, J.H., Bhutani, M.S., Eid, A., Yao, J.C., Phan, A.P., Halpin, A., Suzuki, A., Taketa, T., Thall, P.F., Swisher, S.G.

“…The contribution of induction chemotherapy (IC) before preoperative chemoradiation for esophageal cancer (EC) is not known. We hypothesized that IC would…”
Get full text

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies by Qazilbash, M H, Wieder, E, Thall, P F, Wang, X, Rios, R, Lu, S, Kanodia, S, Ruisaard, K E, Giralt, S A, Estey, E H, Cortes, J, Komanduri, K V, Clise-Dwyer, K, Alatrash, G, Ma, Q, Champlin, R E, Molldrem, J J

“…PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes…”
Get full text

Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC) by Hoffe, S., Frakes, J.M., Aguilera, T.A., Czito, B., Palta, M., Brookes, M., Schweizer, C., Colbert, L., Moningi, S., Bhutani, M.S., Pant, S., Tzeng, C.W., Tidwell, R.S., Thall, P., Yuan, Y., Moser, E.C., Holmlund, J., Herman, J., Taniguchi, C.M.

Get full text

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients by Andersson, B S, Thall, P F, Valdez, B C, Milton, D R, Al-Atrash, G, Chen, J, Gulbis, A, Chu, D, Martinez, C, Parmar, S, Popat, U, Nieto, Y, Kebriaei, P, Alousi, A, de Lima, M, Rondon, G, Meng, Q H, Myers, A, Kawedia, J, Worth, L L, Fernandez-Vina, M, Madden, T, Shpall, E J, Jones, R B, Champlin, R E

“…We hypothesized that IV busulfan (Bu) dosing could be safely intensified through pharmacokinetic (PK-) dose guidance to minimize the inter-patient variability…”
Get full text

Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience by Yilmaz, M, Chemaly, R F, Han, X Y, Thall, P F, Fox, P S, Tarrand, J J, De Lima, M J, Hosing, C M, Popat, U R, Shpall, E, Champlin, R E, Qazilbash, M H

“…Disseminated adenoviral infection (AI) is associated with profound immunosuppression and poor outcome after allogeneic hematopoietic SCT (allo-HSCT). A better…”
Get full text

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan–fludarabine conditioning for allogeneic stem cell transplantation by Konopleva, M, Benton, C B, Thall, P F, Zeng, Z, Shpall, E, Ciurea, S, Kebriaei, P, Alousi, A, Popat, U, Anderlini, P, Nieto, Y, Parmar, S, Qiao, W, Chen, J, Rondon, G, McMullin, B, Wang, R-Y, Lu, H, Schober, W, Woodworth, G, Gulbis, A, Cool, R, Andreeff, M, Champlin, R

“…We hypothesized that during conditioning chemotherapy for allogeneic stem cell transplant (allo-SCT), the disruption of stromal–leukemia interactions using…”
Get full text

A phase I trial of mesenchymal stem cells transfected with a plasmid secreting interferon beta in advanced ovarian cancer by Olson, A, Marini, F, Westin, S, Coleman, R, Thall, P, Al Jahdami, V, Qazilbash, M, Rezvani, K, Timmons, M, Heese, L, Wang, R, Champlin, R, Shpall, E, Andreeff, M

Get full text

Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL by Kebriaei, P, Madden, T, Wang, X, Thall, P F, Ledesma, C, de Lima, M, Shpall, E J, Hosing, C, Qazilbash, M, Popat, U, Alousi, A, Nieto, Y, Champlin, R E, Jones, R B, Andersson, B S

“…We investigated the administration of i.v. BU combined with melphalan (Mel) in patients with ALL undergoing allogeneic hematopoietic SCT. Forty-seven patients…”
Get full text

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma by Shah, N, Thall, P F, Fox, P S, Bashir, Q, Shah, J J, Parmar, S, Lin, P, Kebriaei, P, Nieto, Y, Popat, U R, Hosing, C M, Cornelison, A, Shpall, E J, Orlowski, R Z, Champlin, R E, Qazilbash, M H

Get full text

Phase I II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome by de Lima, M, Champlin, R E, Thall, P F, Wang, X, Martin, T G, Cook, J D, McCormick, G, Qazilbash, M, Kebriaei, P, Couriel, D, Shpall, E J, Khouri, I, Anderlini, P, Hosing, C, Chan, K W, Andersson, B S, Patah, P A, Caldera, Z, Jabbour, E, Giralt, S

“…We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative…”
Get full text

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia by Konopleva, Marina, Thall, Peter F, Yi, Cecilia Arana, Borthakur, Gautam, Coveler, Andrew, Bueso-Ramos, Carlos, Benito, Juliana, Konoplev, Sergej, Gu, Yongchuan, Ravandi, Farhad, Jabbour, Elias, Faderl, Stefan, Thomas, Deborah, Cortes, Jorge, Kadia, Tapan, Kornblau, Steven, Daver, Naval, Pemmaraju, Naveen, Nguyen, Hoang Q, Feliu, Jennie, Lu, Hongbo, Wei, Caimiao, Wilson, William R, Melink, Teresa J, Gutheil, John C, Andreeff, Michael, Estey, Elihu H, Kantarjian, Hagop

“…We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs…”
Get full text

Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine by Estey, E, Thall, P F, Pierce, S, Kantarjian, H, Keating, M

“…To determine the effect of omission of cytarabine (ara-C) from treatment of newly diagnosed acute promyelocytic leukemia (APL), which allows administration of…”
Get more information

Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects by THALL, P. F, CHAMPLIN, R. E, ANDERSSON, B. S

“…We evaluated the 100-day mortality rates associated with busulfan-based myeloablative conditioning regimens based on data from 1812 chronic myelogenous…”
Get full text

A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials by Thall, Peter F., Russell, Kathy E.

“…We propose a design strategy for single-arm clinical trials in which the goals are to find a dose of an experimental treatment satisfying both safety and…”
Get full text

Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes by Thall, P F, Simon, R M, Estey, E H

“…We present a Bayesian approach for monitoring multiple outcomes in single-arm clinical trials. Each patient's response may include both adverse events and…”
Get more information

Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer by Mathew, P, Thall, P F, Wen, S, Bucana, C, Jones, D, Horne, E, Oh, W K, Morris, M J, Lee, Y-C, Logothetis, C J, Lin, S-H, Fidler, I J

“…In a placebo-controlled randomised study of the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate and docetaxel in metastatic…”
Get full text

A Randomized Phase III Trial Of Busulfan + Melphalan (Bu-Mel) Vs Melphalan Alone For Multiple Myeloma: Longer PFS In The Bu-Mel Arm by Qazilbash, M.H, Bashir, Q, Thall, P, Kebriaei, P, Shah, N, Patel, K, Andersson, B.S, Nieto, Y, Valdez, B, Parmar, S, Delgado, R, Shah, J, Orlowski, R.Z, Champlin, R.E

Get full text

Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit by PRICE, K. J, THALL, P. F, KISH, S. K, SHANNON, V. R, ANDERSSON, B. S

“…Although hematopoietic stem cell transplantation (HSCT) can be curative in patients with certain malignancies, survival is poor if the recipient becomes…”
Get full text